Health ❯ Pharmaceuticals ❯ Drug Regulation

FDA

Compounded Drugs Leadership Changes Compounding Pharmacies Enforcement Orders Peptide Drugs Tirzepatide Bladder Cancer Nasal Decongestants Class II Recall Paracetamol

9 ARTICLES

2w ago

FDA Advisory Panel Narrowly Backs Compounding of Four Unapproved Peptides

The nonbinding vote forces the FDA to decide over coming months whether to allow regulated pharmacy compounding despite agency scientists’ warnings about limited safety data.

8 ARTICLES

last mo.

FDA Scientists Say Evidence Lacks for Allowing Seven Popular Peptides in Compounding

10 ARTICLES

2mo ago

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

9 ARTICLES

6mo ago

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

6 ARTICLES

9mo ago

Ascend Recalls 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

3 ARTICLES

last yr.

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy

FDA

FDA Advisory Panel Narrowly Backs Compounding of Four Unapproved Peptides

FDA Scientists Say Evidence Lacks for Allowing Seven Popular Peptides in Compounding

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

Ascend Recalls 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

Wegovy Prescriptions Surge as FDA Ban Cuts Into Copycats

FDA Flags Possible License Revocation for Sarepta’s Elevidys

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

FDA Moves to Ban Ineffective Cold Medicine Ingredient

FDA Proposes Removal of Ineffective Oral Phenylephrine from Cold Medicines

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy